Skip to main content
. 2021 Nov 12;10(11):3141. doi: 10.3390/cells10113141

Figure 2.

Figure 2

Medium- and long-chain plasma acylcarnitines altered in AMD patients. Plasma levels of six acylcarnitines that were higher in NVAMD patients compared to either IAMD patients or controls. Kruskal–Wallis tests were used for pairwise comparisons and p-values are shown above comparison brackets. The molecular identities of these acylcarnitines have been confirmed at MSI level 2.